Artificial Heart Market (2026 - 2033)

Artificial Heart Market Summary

The global artificial heart market size was estimated at USD 3.5 billion in 2025 and is projected to grow from USD 3.8 billion in 2026 to USD 8.1 billion by 2033, growing at a CAGR of 11.3% from 2026 to 2033. The North America dominated the market, accounting for a revenue share of 64.0% in 2025. Some of the key factors driving the market are the rising prevalence of heart failure and other cardiac disorders, the shortage of donor organs for heart transplantation, and recent developments in medicine.

According to an article published by the British Society of Echocardiography in February 2025, nearly 7.6 million people were suffering from heart or circulatory disease in the UK, and more than a million people were living with the risk of heart failure. With the global population aging, there is a growing need for cardiac care and devices such as artificial hearts.

Increased knowledge among patients and healthcare professionals about the benefits of an artificial heart in extending and enhancing quality of life is driving market acceptance. Furthermore, the availability of advanced artificial heart implants in certain regions at lower costs than traditional transplantation is another key factor driving medical tourism for cardiac treatment. For instance, according to an article published by the India Cardiac Surgery Site, the average cost of a ventricular assist device or artificial heart transplant in India was estimated at around USD 54,000 to USD 98,000.

Technological breakthroughs in materials science, robotics, and biotechnology have led to the creation of more advanced heart devices, driving market expansion. The development of fully implantable artificial hearts, such as the SynCardia Total Artificial Heart, which provides circulatory support for patients with end-stage biventricular heart failure, represents a significant innovation in the industry. These devices offer patients a longer-term solution than temporary assist devices, showcasing the ongoing advancement in artificial heart technology. Collaboration among research centers, medical device manufacturers, and academic institutions is driving the development of more innovative artificial heart technologies.

The ongoing shortage of donor organs for heart transplantation has created an unmet need for patients with end-stage heart failure, making the artificial heart a practical alternative. According to Oxford University Press, over 64 million people worldwide suffer from heart failure, with only 6,000 receiving a donor heart. This scarcity necessitates the development and use of an artificial heart to sustain patients while they wait for a suitable donor organ. According to the U.S. Health Resources & Services Administration and the Organ Procurement and Transplantation Network, around 3,436 patients are waiting for transplants.

Analyst Perspective

The market is experiencing steady growth, driven by increasing product innovation, expanding healthcare settings, and the rising prevalence of heart failure. The factors driving market growth are increased awareness among both patients and doctors, along with the presence of affordable treatments in new medical tourism hubs, which are helping the trend gain more acceptance. Ongoing developments in biocompatible materials, sensors, miniaturization, and fully implantable devices are improving device performance. Business alliances, innovations, and geographic expansion by key players are all contributing to the market's positive outlook. Despite regulatory problems, the future demand for cardiac replacement technology is very positive.

Type Insights

The left ventricular assist device (LVAD) segment held the largest market share of over 77.5% in 2025. The rising global prevalence of heart failure has significantly contributed to LVAD growth. As heart failure cases increase, there is a growing demand for advanced cardiac support devices, such as LVADs, to improve patient outcomes and quality of life. For instance, Abbott's introduction of the HeartMate 3 LVAD, which incorporates magnetically levitated rotor technology, has significantly reduced the risk of pump thrombosis and improved patient outcomes compared to earlier generations of LVADs.

Ongoing technological advancements in LVADs, such as miniaturization, improved durability, and enhanced control algorithms, have made these devices effective, safer, and suitable for a broader range of patients. Clinical studies, such as the MOMENTUM 3 trial comparing the HeartMate 3 LVAD to the HeartMate II, have demonstrated superior outcomes with newer LVAD technologies, leading to increased adoption and market share. The significant improvement in patient outcomes, including survival rates, quality of life, and functional capacity, with LVAD therapy has fueled demand for LVAD therapy among heart failure patients and healthcare providers. The significant improvement in patient outcomes, including survival rates, quality of life, and functional capacity, with LVAD therapy has fueled demand for LVAD therapy among heart failure patients and healthcare providers.

The Total Artificial Heart (TAH) segment is anticipated to witness the fastest CAGR of approximately 14.5% during the forecast period, owing to the increasing prevalence of advanced heart failure, driven by factors such as aging populations, rising incidence of cardiovascular diseases, and improved survival rates of patients with chronic heart conditions, which has created a larger patient pool for TAH therapy. Continuous advancements in TAH technology, including improved biocompatibility, miniaturization, enhanced durability, and sophisticated control algorithms, have made these devices more reliable, safer, and suitable for a broader range of patients. For instance, in February 2025, a PubMed-indexed 20-year single-center study (PMID: 39283166) involving 196 patients who were implanted with the SynCardia Total Artificial Heart reported that the device remains a viable, life-sustaining option for patients with irreversible biventricular heart failure awaiting transplantation. The study found that more than one-third of patients were successfully bridged to heart transplantation, underscoring the clinical relevance of TAH systems in addressing donor heart shortages and supporting patients with end-stage heart failure.

According to Daniel Timms, Founder and Chief Technology Officer of BiVACOR Inc., “There is a huge gap between available treatment options and the number of patients with severe heart failure. Initiating human clinical work for the BiVacor TAH is the first step to address critical patient needs from this noncurative disease.” BiVACOR focuses on developing a total artificial heart (TAH) to perform all functions of the patient’s failing heart.

Therapy Insights

The destination therapy segment accounted for the largest revenue share, exceeding 35.0% in 2025, and is expected to witness the fastest CAGR during the forecast period. This is due to the increasing prevalence of advanced heart failure patients who are ineligible for heart transplantation or other therapies. This patient population represents a significant unmet medical need, driving demand for long-term mechanical circulatory support provided by an artificial heart. Companies are focused on developing next-generation artificial hearts with enhanced features, such as remote monitoring capabilities, improved battery life, and reduced device-related complications. These advancements aim to improve patient outcomes and expand the reach of destination therapy (DT) to a wider patient population. For instance, in February 2024, results from the ELEVATE Registry, published in the Journal of the American College of Cardiology, reported a 63.3% five-year survival rate among patients with Abbott's HeartMate 3 LVAD in real-world clinical practice. The findings highlight the growing effectiveness of durable mechanical circulatory support as a long-term treatment option for advanced heart failure patients who are ineligible for heart transplantation, supporting the increasing adoption of destination therapy.

Expanded clinical indications and regulatory approvals have further fueled the growth of the DT segment. Regulatory agencies such as the FDA have approved artificial hearts, including LVADs and the Total Artificial Heart, specifically for destination therapy use. Clinical evidence supporting destination therapy devices and positive outcomes has bolstered confidence among healthcare professionals and patients. Long-term studies and real-world data have demonstrated significant improvements in survival rates, reduced hospitalization rates, and enhanced patient well-being with DT interventions.

Regional Insights

North America dominated the market, accounting for a revenue share of 64.0% in 2025 and is expected to witness the fastest CAGR during the forecast period. Advanced healthcare infrastructure, the increasing prevalence of cardiovascular diseases, favorable reimbursement policies, and technological advancements in the region drive market growth.

U.S. Artificial Heart Market Trends

The artificial heart market in the U.S. dominated North America, with major players like Abbott, BiVacor, and SynCardia leading innovations in LVADs and Total Artificial Heart. For instance, in July 2024, surgeons at the Texas Heart Institute in Houston, Texas, successfully implanted the world's first BiVACOR Total Artificial Heart in a patient with end-stage heart failure as part of the U.S. Food and Drug Administration's Early Feasibility Study. The milestone highlights North America's leadership in artificial heart innovation, supported by advanced healthcare infrastructure, robust regulatory pathways, and ongoing investment in next-generation cardiac replacement technologies, reinforcing the region's dominant market position.

According to the Centers for Disease Control and Prevention, heart failure in the U.S. causes 6.2 million cases yearly, resulting in approximately 380,000 deaths and USD 30.7 billion in medical costs. However, due to a limited donor heart supply, only 3% of these patients receive a transplant, highlighting the need for a reliable mechanical heart replacement solution such as artificial heart transplantation.

Europe Artificial Heart Market Trends

The artificial heart market in Europe is expected to experience robust growth over the forecast period, owing to an aging population, rising prevalence of heart failure, supportive healthcare policies, and technological advancements. The European Heart Health Charter, initiated by the European Society of Cardiology and the European Heart Network, aims to enhance cardiovascular health by preventing and ensuring treatment for those in need. It recommends a collaborative framework to reduce premature and preventable cardiovascular disease events in the European Union and in countries of the WHO European Region. Moreover, the Heart Failure policy and practice in Europe aims to support advocates with a clear outline of policy issues and best practices in heart failure across 11 European countries.

The UK artificial heart market is expected to see lucrative growth owing to the rising prevalence of cardiovascular disorders among the country’s population. As cardiovascular diseases remain a significant health concern in the country, the need for advanced treatment options like an artificial heart continues to grow. According to the British Heart Foundation, approximately 4 million men and 3.6 million women in the country suffer from heart and circulatory diseases. The organization also projects that an aging and growing population could result in an additional 1 million people living in these conditions by 2030.

The artificial heart market in France is anticipated to grow significantly, driven by increased emphasis on medical technology adoption. France has a strong focus on adopting cutting-edge medical technologies to enhance patient care and outcomes. This emphasis on innovation has led to increased acceptance of artificial heart devices as viable treatment options for patients with severe cardiac conditions. There are notable advancements in LVAD technology, with companies in the region, such as CARMAT, focusing on developing a bioprosthetic artificial heart. Regulatory support from agencies like ANSM (Agence Nationale de Sécurité du Médicament) facilitates market access for innovative devices.

Asia Pacific Artificial Heart Market Trends

The artificial heart market in the Asia Pacific region is experiencing growth due to rising cardiovascular disease rates driven by changing lifestyles, dietary habits, and an aging population. This rise in cardiac disorders is driving significant demand for advanced cardiac care solutions, including artificial hearts. There is a growing awareness of cardiovascular health in the region, leading to earlier detection and treatment of heart conditions. This heightened awareness drives the demand for advanced cardiac therapies, including artificial hearts.

Australia artificial heart market is expected to show lucrative growth owing to the high incidence of cardiovascular disorders among the population, especially in older age groups, which drives the demand for artificial heart devices. According to the Minister's Department of Health and Aged Care, the Australian Government is investing USD 50 million to develop and commercialize the world's most advanced artificial heart, which could reduce global heart failure deaths and contribute USD 1.8 billion to Australia.

The artificial heart market in India is expected to show lucrative growth owing to the improving healthcare access, rising disposable income, and advancements in medical technology. India has a large population with a growing burden of cardiovascular diseases, making it one of the key drivers for artificial heart adoption. The increasing prevalence of risk factors such as hypertension, diabetes, and obesity contributes to a higher incidence of heart-related conditions, creating a demand for advanced cardiac therapies like an artificial heart. According to the World Health Organization (WHO), cardiovascular diseases (CVDs) remained the leading cause of death globally, accounting for an estimated 19.8 million deaths in 2022, representing approximately 32% of all deaths worldwide. India is responsible for one-fifth of these fatalities, especially in younger populations.

Latin America Artificial Heart Market Trends

The artificial heart market in Latin America is experiencing a rise in cardiovascular diseases, including coronary artery disease and heart failure. This prevalence of cardiac conditions is driving the demand for artificial heart devices in the region. Similar to global trends, this region is also witnessing an aging population, leading to cardiovascular issues and other heart-related illnesses.

Mexico artificial heart market is expected to grow significantly owing to the prevalence of cardiovascular diseases. According to Mexico's National Institute of Statistics and Geography (INEGI) in August 2025, heart disease remained the leading cause of death in 2024, accounting for 192,563 fatalities nationwide. Moreover, the persistently high cardiovascular mortality burden, coupled with ongoing investments in healthcare infrastructure and technological capabilities, presents opportunities for market growth.

MEA Artificial Heart Market Trends

The artificial heart market in MEA is experiencing rapid growth, driven by government investments in modernizing healthcare facilities and services. This progress creates opportunities for the adoption of advanced medical technologies, such as artificial hearts. According to the Saudi Health Council, the Middle East experiences 309 deaths per 100,000 individuals from ischemic heart disease and hypertensive heart disease, compared to 204 per 100,000 in North America and 187 per 100,000 in Western Europe.

The Saudi Arabia artificial heart market is anticipated to witness significant growth, driven by rising heart disease rates due to aging and lifestyle factors. The government in Saudi Arabia focuses on healthcare infrastructure development and investment in research and development, further supporting market growth. Initiatives aimed at improving cardiac care and reducing cardiovascular mortality rates are expected to drive the adoption of artificial hearts in the country. In January 2025, the Saudi Minister of Health reported that the implementation of the Kingdom's modern healthcare model had contributed to a 40% reduction in premature deaths from chronic diseases, reflecting significant progress in cardiovascular disease prevention and treatment. Furthermore, Saudi Vision 2030 has expanded healthcare coverage to 97.4% of the population clusters across the Kingdom, strengthening access to specialized cardiac services and creating a favorable environment for the adoption of advanced technologies such as artificial hearts and mechanical circulatory support devices.

Key Artificial Heart Companies Insights

The market is dynamic and competitive, with several key players vying for market share. The companies in this market are focusing on research and development, strategic partnerships, and product launches. The commitment to advancing cardiac care through technological innovations has contributed to a substantial market share in the artificial heart sector. For instance, in December 2024, BiVACOR completed the first phase of its U.S. FDA Early Feasibility Study, with five patients receiving its Total Artificial Heart, all of whom were successfully bridged to donor heart transplantation. Following these results, the FDA authorized the expansion of the study to an additional 15 patients, underscoring the growing clinical validation of next-generation artificial heart technologies and the industry's commitment to advancing treatment options for patients with end-stage heart failure.

Key Artificial Heart Companies

The following key companies have been profiled for this study on the artificial heart market:

• SynCardia Systems, LLC

• CARMAT

• BiVACOR Inc.

• RealHeart

• Abbott

• ABIOMED (Johnson & Johnson Services Inc.)

• Jarvik Heart, Inc.

• LivaNova PLC

• Getinge

• Terumo Corporation

Recent Developments

• In July 2025, CARMAT received CE Mark approval under the Medical Device Regulation (MDR) for its Aeson artificial heart in Europe. The certification validates compliance with the European Union's most stringent medical device requirements. It strengthens CARMAT's commercial market position, supporting broader adoption of advanced total artificial heart technologies across the region.

• In February 2024, BiVacor, an Australian medical device company, received a USD 13 million grant from the Australian Government's Medical Research Future Fund to support its Total Artificial Heart program, a long-term therapy for patients with severe biventricular heart failure.

Artificial Heart Market Report Scope

Global Artificial Heart Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global artificial heart market report based on type, therapy, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • LVADs

  • Heart-lung Machine

  • Total Artificial Heart

• Therapy Outlook (Revenue, USD Billion, 2021 - 2033)

  • Bridge to Transplant

  • Destination Therapy

  • Bridge to Decision

  • Others

• Regional Outlook (Revenue, USD Billion, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait